KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Assets (2016 - 2025)

Historic Assets for BeOne Medicines (ONC) over the last 11 years, with Q3 2025 value amounting to $7.6 billion.

  • BeOne Medicines' Assets rose 3089.98% to $7.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $7.6 billion, marking a year-over-year increase of 3089.98%. This contributed to the annual value of $5.9 billion for FY2024, which is 199.19% up from last year.
  • BeOne Medicines' Assets amounted to $7.6 billion in Q3 2025, which was up 3089.98% from $6.3 billion recorded in Q2 2025.
  • Over the past 5 years, BeOne Medicines' Assets peaked at $8.5 billion during Q4 2021, and registered a low of $5.3 billion during Q3 2021.
  • Over the past 5 years, BeOne Medicines' median Assets value was $5.8 billion (recorded in 2024), while the average stood at $6.2 billion.
  • Per our database at Business Quant, BeOne Medicines' Assets soared by 5239.95% in 2021 and then tumbled by 3578.39% in 2022.
  • Over the past 5 years, BeOne Medicines' Assets (Quarter) stood at $8.5 billion in 2021, then tumbled by 35.78% to $5.5 billion in 2022, then rose by 5.91% to $5.8 billion in 2023, then grew by 1.99% to $5.9 billion in 2024, then rose by 28.91% to $7.6 billion in 2025.
  • Its Assets stands at $7.6 billion for Q3 2025, versus $6.3 billion for Q2 2025 and $5.8 billion for Q1 2025.